BRAINSTORM CELL THERAPUTC
BCLI
BCLI was delisted on the 17th of July, 2025.
37 hedge funds and large institutions have $7.61M invested in BRAINSTORM CELL THERAPUTC in 2019 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 11 increasing their positions, 5 reducing their positions, and 3 closing their positions.
120% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 5
0.18% less ownership
Funds ownership: 0.78% → 0.59% (-0.18%)
3% less funds holding
Funds holding: 38 → 37 (-1)
27% less capital invested
Capital invested by funds: $10.5M → $7.61M (-$2.86M)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
100% less call options, than puts
Call options by funds: $7K | Put options by funds: $2.12M
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Group One Trading
Chicago,
Illinois
|
+$250K |
| 2 |
BlackRock
New York
|
+$156K |
| 3 |
Wolverine Trading
Chicago,
Illinois
|
+$126K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$121K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$104K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$2.28M |
| 2 |
PVH
Psagot Value Holdings
Tel Aviv,
Israel
|
-$240K |
| 3 |
CIBC Private Wealth Group
Atlanta,
Georgia
|
-$194K |
| 4 |
EMG
ETF Managers Group
Summit,
New Jersey
|
-$86.4K |
| 5 |
DG
Delek Group
Herzliya,
Israel
|
-$25K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Wells Fargo
San Francisco,
California
| $20K | +$524 | +9 | +3% |
|
27
UBS Group
Zurich,
Switzerland
| $20K | +$19.7K | +338 | New |
|
28
First Manhattan
New York
| $13K | – | – | – |
|
|
SPIA
29
Steward Partners Investment Advisory
New York
| $9K | +$9.72K | +167 | New |
|
30
Bank of Montreal
Toronto,
Ontario, Canada
| $8K | – | – | – |
|
|
IFAM
31
Institutional & Family Asset Management
Fort Collins,
Colorado
| $8K | – | – | – |
|
|
ASN
32
Advisory Services Network
Atlanta,
Georgia
| $2K | – | – | – |
|
|
VFA
33
Valeo Financial Advisors
Carmel,
Indiana
| $2K | – | – | – |
|
|
KFS
34
Kelly Financial Services
Braintree,
Massachusetts
| $1.31K | – | – | – |
|
35
Citigroup
New York
| $1K | – | – | – |
|
36
US Bancorp
Minneapolis,
Minnesota
| $1K | – | – | – |
|
|
PVH
37
Psagot Value Holdings
Tel Aviv,
Israel
| – | -$240K | -3,683 | Closed |
|
|
KPW
38
Kore Private Wealth
New York
| – | -$17K | -267 | Closed |
|
|
LPC
39
Loeb Partners Corp
New York
| – | -$5K | -80 | Closed |
|
BCLI Hedge Fund Activity: Q2 2019 in Review
37 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in BRAINSTORM CELL THERAPUTC (BCLI) for Q2 2019, worth a combined $7.61M — down 27% from $10.5M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of BCLI and 2 opened new positions — a net loss of 1 holder — while 5 trimmed existing stakes and 11 added.
The largest buyer was Group One Trading, adding an estimated $250K. The largest seller was Sabby Management, cutting an estimated $2.28M.
- 37 institutional investors held BRAINSTORM CELL THERAPUTC (BCLI) as of Q2 2019, down from 38 in Q1 2019.
- Funds reported $7.61M of BRAINSTORM CELL THERAPUTC stock for Q2 2019, down 27% quarter-over-quarter.
- 2 funds opened new BRAINSTORM CELL THERAPUTC positions in Q2 2019 and 3 closed out, a net change of -1 holder.
- The largest BRAINSTORM CELL THERAPUTC buyer in Q2 2019 was Group One Trading, an estimated $250K added.
- The largest BRAINSTORM CELL THERAPUTC seller in Q2 2019 was Sabby Management, an estimated $2.28M sold.
Based on aggregated 13F filings for Q2 2019.